Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study.

Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study.

Osimertinib showed encouraging efficacy in patients with advanced EGFR T790M-positive NSCLC in previous randomized controlled trials. This real-world study aimed to evaluate the effectiveness and safety of osimertinib in a real-world setting. This observational study (NCT03133234) included 74 patien...

Full description

Bibliographic Details
Main Authors:	Yabing Cao, Xibin Qiu, Guangli Xiao, Hao Hu, Tongyu Lin
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0221575

Similar Items

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
by: Hanping Wang, et al.
Published: (2020-03-01)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
by: Motohiro Tamiya, et al.
Published: (2021-05-01)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
by: Yen-Hsiang Huang, et al.
Published: (2021-06-01)

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
by: Zhou R, et al.
Published: (2021-04-01)

Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
by: Beung-Chul Ahn, et al.
Published: (2021-07-01)

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
by: Yen-Hsiang Huang, et al.
Published: (2021-08-01)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
by: Xiaoying Zhang
Published: (2021-06-01)

Osimertinib in NSCLC: Real-World Data From New Zealand
by: Yeojeong Jane So, MbChB, FRACP, et al.
Published: (2020-06-01)

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
by: Cristina M. Merkhofer, MD, MHS, et al.
Published: (2021-06-01)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
by: MuYun Peng, et al.
Published: (2020-09-01)

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
by: Bin-Chi Liao, MD, et al.
Published: (2021-01-01)

Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice.
by: Dong Kyu Oh, et al.
Published: (2019-01-01)

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
by: Bing Wei, et al.
Published: (2019-05-01)

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
by: Peng D, et al.
Published: (2021-02-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
by: Lin-Peng Zheng, et al.
Published: (2018-11-01)

Primary resistance to osimertinib despite acquired T790M
by: Ling‐Kai Chang, et al.
Published: (2020-03-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
by: Marcin Skrzypski, et al.
Published: (2017-09-01)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
by: Akihiro Yoshimura, et al.
Published: (2019-03-01)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
by: Changhui Li, et al.
Published: (2021-05-01)

Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.
by: Yabing Cao, et al.
Published: (2014-01-01)

Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer
by: Maria Gabriela O. Fernandes, et al.
Published: (2021-05-01)

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
by: Denis MG, et al.
Published: (2020-12-01)

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs
by: Li Ma, et al.
Published: (2021-03-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
by: Bin Zou, et al.
Published: (2017-07-01)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
by: Hongjing Zang, et al.
Published: (2020-04-01)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
by: Silvia La Monica, et al.
Published: (2017-12-01)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
by: Qiufan Zheng, et al.
Published: (2020-02-01)

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial–mesenchymal transition
by: Kejun Liu, et al.
Published: (2021-05-01)

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
by: Vanita Noronha, et al.
Published: (2017-01-01)

Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment
by: Xin Tang, et al.
Published: (2021-09-01)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
by: Yosuke Miyashita, et al.
Published: (2021-02-01)

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment
by: Po‐Lan Su, et al.
Published: (2019-10-01)

Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC
by: Wu Y, et al.
Published: (2017-07-01)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
by: Chenguang Li, et al.
Published: (2018-08-01)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
by: Saad N, et al.
Published: (2017-03-01)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
by: Miriam Blasi, et al.
Published: (2021-03-01)

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report
by: Shinichi Miyazaki, et al.
Published: (2020-08-01)

Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy
by: Yulong Fu, et al.
Published: (2021-02-01)